Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial of the Combination of Everolimus (RAD001) and Bortezomib (VELCADE) for Relapsed or Refractory Lymphoma

NCT00671112 is registered in ClinicalTrials.gov with Brian Hill, MD, PhD as lead sponsor.

NCT NCT00671112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00671112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial of the Combination of Everolimus (RAD001) and Bortezomib (VELCADE) for Relapsed or Refractory Lymphoma
Lead sponsor
Brian Hill, MD, PhD
Phase
Phase 1
Overall status
Terminated
Start date
June 30, 2008
Completion date
Not reported
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

714leukemia, lymphoma